China's self-developed AIDS vaccine enters Phase I clinical

the DNA-Tiantanpox Miao compound AIDS vaccine jointly developed by the China center fordiseaseprevention and control and the Beijing Institute of Biological Products began the first group of volunteers to be vaccinated at theof ConcordHospital in Beijing on December 1This means that China's independent intellectual property rights of aids vaccine began to carry out Phase I clinical trialsThis is also the world's only ongoing clinical trial of the replication vector AIDS vaccineAccording to experts from the ChinaDiseasePrevention and Control Center, the AIDS vaccine includes two components of the DNA vaccine and the replication of the recombinant pox virus vaccine, which has China's independent intellectual property rightsThe vaccine was originally selected from CRF-07, the most widely prevalent HIV strain in China, and included four genes: gag, pol, env and nefThe vector of the vaccine chose the Temple of Heaven's pox seed virus, because the pox seed virus has been widely used in China's smallpox vaccine, the safety has been used by hundreds of millions of people fully verifiedThis recombinant AIDS vaccine has passed the strict identification of relevant parties before the clinical trial, the quality of qualified, its Phase I clinical trial has been approved by the National FoodDrug administrationRegulatory AdministrationThe vaccine development has received funding from the National "863" program and related EU projectsAccording to reports, the international AIDS vaccine research has been more than 20 years, although the cost of more than 100 clinical trials of such a vaccine, but there is no effective vaccine, there are two have entered the Phase III clinical trial of the vaccine have failed Up to now, the internationally declared failure of AIDS vaccines are protein vaccine or non-replicated vector vaccine, belong to the dead vaccine With the international epidemic of AIDS vaccine design concept and technology route is very different from China's researchers this clinical trial is a replication of the pox virus vector, belongs to the live vaccine, can cause a strong immune response in animals